macular telangiectasia

News

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia type 2.

News

There has been a major data security lapse at the UK Biobank, with "de-identified" data from its 500,000 volunteers listed for sale in China.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.